Metsera's (MTSR) Amylin Agonist Data Leads to Price Target Increase

Metsera Inc. (NASDAQ:MTSR) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 20, BofA raised the firm’s price target on Metsera to $45 from $38, while keeping a Buy rating on the shares after the company announced the first round of clinical data on its amylin agonist, called MET-233i.

Metsera then later released its Q2 2025 financial results in the same month. The company reported cash reserves of $530.9 million as of June 30, compared to $352.4 million as of December 31, 2024, and is expected to provide an operational runway through 2027. In Q2, Metsera reported positive Phase 1 data for MET-233i, a once-monthly amylin analog.

The company also has MET-097i, a monthly GLP-1 receptor agonist, with Phase 3 trials expected to begin in late 2025. The release of topline data from the VESPER-1 and interim data from VESPER-3 trials is anticipated in late 2025 to inform the dosing regimen for the Phase 3 trials. Additionally, Metsera’s oral peptide platform, including MET-097o and MET-224o, is expected to present four-week data later in the year.

Metsera Inc. (NASDAQ:MTSR) is a clinical-stage biotechnology company that develops injectable and oral nutrient-stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.